Tracking Hot Flash Treatment Outcomes in Canadian Women
Treatments studied
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You live in Canada
- You are experiencing hot flashes related to menopause
- Your doctor has just prescribed fezolinetant and you haven't started taking it yet
- Your liver function tests were normal within the last 3 months
- You speak English or French fluently
- You can use a smartphone, tablet, or computer and have internet access
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a non-hormonal pill called fezolinetant to see if it reduces hot flashes in Indian women going through menopause. It may offer a new option for women who cannot or prefer not to use hormone therapy.
This study tests a medication called fezolinetant to see if it reduces hot flashes in men undergoing hormone therapy for prostate cancer. If you experience frequent hot flashes, this treatment might help alleviate them.
This trial tests whether a dietary supplement can reduce hot flashes in women who are in late perimenopause or early postmenopause. If you are experiencing frequent hot flashes, this could help you find relief.
This trial tests a non-hormonal pill called fezolinetant to reduce hot flashes in men with prostate cancer who are on hormone therapy. If you have daily, bothersome hot flashes, this study may help you find relief.
This study tests a medication called fezolinetant to see if it helps with hot flashes and also looks at its effects on blood vessels and the brain. It is for women who are going through menopause and having frequent moderate to severe hot flashes.
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
Hear when a new Hot Flashes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.